Pharmaceutical

NextCure and Simcere partner to develop SIM0505 for solid tumours

NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating solid tumours.

Jun 17, 2025 - 06:00
NextCure and Simcere partner to develop SIM0505 for solid tumours
NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating solid tumours.
Read the original article

Tags:

Previous Article

NIH Launches New Research Initiative to Investigate PFAS Effects on Male Reprodu...

Next Article

Supernus makes depression drug play with $795m Sage buyout

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Idorsia’s Quviviq receives marketing authorisation from Health Canada

Idorsia’s Quviviq receives marketing authorisation from...

May 4, 2023

Vistagen obtains Canadian Notice of Allowance for AV-101 patent

Vistagen obtains Canadian Notice of Allowance for AV-10...

Jul 15, 2023

Biogen proposes acquisition of partner Sage Therapeutics

Biogen proposes acquisition of partner Sage Therapeutics

Jan 14, 2025